Synthetic GHRH(1–29), the minimal active GHRH sequence
PRODUCT PROFILE
Sermorelin
£49.00
Sermorelin is synthetic ghrh(1–29), the minimal active ghrh sequence. Researchers examine it in relation to pituitary gh reserve and short-duration ghrh-receptor stimulation.
Why it is distinct
Closest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
- Evidence stageEstablished
- AvailabilityUnavailable
- Batch recordOpen COA
- DispatchConfirmed at checkout
Out of stock
Ask about availabilitySUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Preclinical
BPC-157
£32.99Batch COA availableBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Preclinical
TB-500
£32.99Batch COA availableTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Sermorelin is synthetic ghrh(1–29), the minimal active ghrh sequence. Researchers examine it in relation to pituitary gh reserve and short-duration ghrh-receptor stimulation.
Research focus+
Researchers use it to study how well the pituitary gland can release growth hormone. It acts briefly and differs from compounds designed for a long-lasting effect.
How the mechanism differs+
Reproduces the active N-terminal portion of natural GHRH and depends on a responsive pituitary.
Evidence and limitations+
Has historical human diagnostic and paediatric-development use; current availability and authorisation vary by jurisdiction.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers use it to study how well the pituitary gland can release growth hormone. It acts briefly and differs from compounds designed for a long-lasting effect.
Reproduces the active N-terminal portion of natural GHRH and depends on a responsive pituitary.
Closest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
Has historical human diagnostic and paediatric-development use; current availability and authorisation vary by jurisdiction.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch COA availableShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Early human evidence
GHRP-2
£44.005 mgBatch COA availableTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability -
Experimental
PEG-MGF
£61.002 mgBatch COA availableA modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
UnavailableAsk about availability -
Experimental
IGF-1 LR3
£47.991 mgBatch COA availableDesigned for longer, less binding-protein-restricted IGF signalling than native IGF-1 or IGF-1 DES.
Available · 10 in stockAdd to basket